Commercial Strategy for Radionucleid Diagnositic and Therapeutic NewCo Strategy

Prof. Barry Myers is looking for an MBA student.

Please let him know if you are interested.

Howie

One Semester Two Term Independent Study Project:

Commercial Strategy for Radionucleid Diagnositic and Therapeutic NewCo Strategy

A recent major capital investment in the region is resulting in the creation of new and proprietary radioactive particles for use in clinical practice. These particles can be attached or inserted into a wide variety of molecules (e.g. antibodies, receptor binders, etc.) to serve as diagnostics and enhanced therapeutics. The technical advantage afforded by this investment is significant and as a platform, it has the potential to spin out one or many NewCo's.

You will lead a team that includes, faculty experienced in venture capital, post-doc's with expertise in the radiochemistry, and former entrepreneurs to understand the marketplace and develop a business case for entry into the market.

Please contacted Dr. Barry Myers (barry.myers@duke.edu) if interested.

Barry Myers MD PhD MBA  Professor and Senior Associate Dean for Industrial Partnerships  and Research Commercialization, Pratt School of Engineering  Director Duke Center for Entrepreneurship and Research Commercialization http://www.cerc.duke.edu/  Executive-in-Residence Pappas Ventures  Rm 267 Hudson Engineering Annex Box 90281, Durham NC 27708-0281 (919) 660-5150 (o) (919) 684-4488 (fax)